(IN BRIEF) Sanofi has received a positive recommendation from the European Medicines Agency’s CHMP for the conditional approval of Rezurock to treat late-line chronic graft-versus-host disease in adults and adolescents aged 12 and older. The opinion, based on clinical trial … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged belumosudil, CHMP, CHMP Recommends Conditional EU Authorisation for Sanofi’s Rezurock to Treat Late-Line Chronic GVHD, chronic graft-versus-host disease, clinical trials, conditional marketing authorisation, EU regulatory approval, European Medicines Agency, GVHD, haematology, rare diseases, Rezurock™, ROCK2 inhibitor, ROCKstar study, Sanofi, stem cell transplant
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release
Posted in France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, anti-human thymocyte antibody preparation, anti-thymocyte globulin, belumosudil, biopharmaceutical company, cGVHD, chronic graft-versus-host disease, fibrotic diseases, General Medicines, Harlan Waksal M.D., hematopoietic stem cell mobilizer, immuno-oncology therapies, immunomodulating agent, immunosuppressive, Kadmon Holdings, Mozobil®, Olivier Charmeil, plerixafor, polyclonal, Rezurock™, Sanofi, systemic therapy, Thymoglobulin®, transformative therapies, transplant portfolio
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?